Biondvax Story

<div class='circular--portrait' style='background:#169D0B;color: #E6E6FA;font-size:4em;'>BP</div>
BVXV -- USA Stock  

USD 4.30  0.06  1.38%

In spite of fairly weak fundamental indicators, BiondVax Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in February 2021. Will sophisticated investors continue to hold, or should we expect a sell-off?
Published over a month ago
View all stories for Biondvax Pharma | View All Stories
Does BiondVax Pharmaceuticals (NASDAQ:BVXV) have stable fundamental indicators based on the latest climb?
BiondVax Pharmaceuticals is UNDERVALUED at 7.80 per share with modest projections ahead. BiondVax Pharmaceuticals is unstable given 1 month investment horizon. BiondVax Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.12, which signifies that the company had 0.12% of return per unit of risk over the last month. Our standpoint towards foreseeing the risk of a stock is to use both market data as well as company specific technical data. We were able to break down twenty-one different technical indicators, which can help you to evaluate if expected returns of 1.04% are justified by taking the suggested risk. Use BiondVax Pharmaceuticals mean deviation of 7.0, and Risk Adjusted Performance of (0.05) to evaluate company specific risk that cannot be diversified away.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Biondvax Pharma income statement, its balance sheet, and the statement of cash flows. Potential Biondvax Pharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Biondvax Pharma investors may use each financial statement separately, they are all related. The changes in Biondvax Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Biondvax Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Biondvax Pharma fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Biondvax Pharma performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Biondvax Pharma shares is the value that is considered the true value of the share. If the intrinsic value Biondvax is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Biondvax Pharma.
Please read more on our fundamental analysis page.

What is Biondvax Asset Breakdown?

Biondvax Pharma Ads reports assets on its Balance Sheet. It represents the amount of Biondvax resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect Biondvax volatility, please check the breakdown of all its fundamentals

How Biondvax utilizes its cash?

To perform a cash flow analysis of Biondvax Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Biondvax Pharma is receiving and how much cash it distributes out in a given period. The Biondvax Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Biondvax Pharma Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Biondvax Pharma reported Net Cash Flow from Operations of (69.35 Million) in 2020

Is Biondvax Pharma valued fairly by the market?

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of BiondVax Pharmaceuticals is not uncomon. Institutional investors typically avoid acquiring a high percentage of BiondVax Pharmaceuticals stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of BiondVax is distributed among investors.

Ownership Allocation

The market capitalization of BiondVax Pharmaceuticals is $43.23 Million. BiondVax Pharmaceuticals retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Retail Investors
58.84%
Insiders
37.1%
Retail Investors58.84
Insiders37.1
Institutions4.06

Asset Utilization

One of the ways to look at asset utilization of BiondVax is to check how much profit was generated for every dollar of assets it reports. BiondVax Pharmaceuticals shows a negative utilization of assets of -67.84 percent, losing $0.68 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of BiondVax Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.

Current Assets
70.8 M
Assets Non Current
52.9 M
Current Assets70.84 Million57.25
Assets Non Current52.89 Million42.75

Our take on today BiondVax Pharmaceuticals climb

The kurtosis is down to 22.78 as of today. BiondVax Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize BiondVax Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about BiondVax Pharmaceuticals volatility.

The Bottom Line

While few other entities within the biotechnology industry are still a little expensive, even after the recent corrections, BiondVax Pharmaceuticals may offer a potential longer-term growth to sophisticated investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither pick up nor exit any shares of BiondVax Pharmaceuticals at this time. The BiondVax Pharmaceuticals risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to BiondVax Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Biondvax Pharma Ads. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com